2022
Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey
Rider L, Parks C, Wilkerson J, Schiffenbauer A, Kwok R, Farhadi P, Nazir S, Ritter R, Sirotich E, Kennedy K, Larche M, Levine M, Sattui S, Liew J, Harrison C, Moni T, Miller A, Putman M, Hausmann J, Simard J, Sparks J, Miller F, Akpabio A, Alpizar-Rodriguez D, Berenbaum F, Bulina I, Conway R, Singh A, Duff E, Durrant K, Gheita T, Hill C, Howard R, Hoyer B, Hsieh E, Kibbi L, Kilian A, Kim A, Liew D, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee C, Singh J, Singh N, Ugarte-Gil M, Wallace J, Young K, Bhana S, Costello W, Grainger R, Machado P, Robinson P, Sufka P, Wallace Z, Yazdany J, Foster G, Thabane L, Angevare S, Beesley R, Chock E, Degirmenci B, Felix C, Jin S, Mateus E, Peirce A, Sari E, Tseng R, Wang L, Zamora E. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology 2022, 61: si143-si150. PMID: 35460240, PMCID: PMC9248066, DOI: 10.1093/rheumatology/keac249.Peer-Reviewed Original ResearchConceptsSystemic rheumatic diseasesCOVID-19 vaccinationRisk factorsDisease flareRheumatic diseasesHigher oddsSARS-CoV-2 severityFlare of diseaseIdiopathic inflammatory myopathiesSystemic lupus erythematosusOxford-AstraZeneca vaccineMultivariable logistic regressionHistory of reactionPotential risk factorsPfizer-BioNTech vaccineLarge international studyImmunosuppressive medicationsInternational studiesVaccines surveyAdverse eventsInflammatory myopathiesPolymyalgia rheumaticaProspective cohortPsoriatic arthritisBaseline factors
2021
Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA
Omer SB, Benjamin RM, Brewer NT, Buttenheim AM, Callaghan T, Caplan A, Carpiano RM, Clinton C, DiResta R, Elharake JA, Flowers LC, Galvani AP, Lakshmanan R, Maldonado YA, McFadden SM, Mello MM, Opel DJ, Reiss DR, Salmon DA, Schwartz JL, Sharfstein JM, Hotez PJ. Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. The Lancet 2021, 398: 2186-2192. PMID: 34793741, PMCID: PMC8592561, DOI: 10.1016/s0140-6736(21)02507-1.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineSARS-CoV-2 infectionCOVID-19 vaccination campaignCOVID-19 vaccine acceptanceCOVID-19 vaccine programPfizer-BioNTech vaccineEmergency use authorisationVaccine programVaccine acceptanceVaccination campaignVaccine refusalCommunity transmissionUS FoodDrug AdministrationInadequate uptakeVaccineBehavioral intervention strategiesBest interventionLancet CommissionLow uptakeIntervention strategiesCOVID-19Evidence-based educationFull approvalUS residentsDelayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine
Johnston MS, Galan A, Watsky KL, Little AJ. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine. JAMA Dermatology 2021, 157: 716-720. PMID: 33978670, PMCID: PMC8117061, DOI: 10.1001/jamadermatol.2021.1214.Peer-Reviewed Original ResearchConceptsModerna COVID-19 vaccineInjection site reactionsCOVID-19 vaccineCutaneous injection-site reactionsSecond vaccine doseCase series studySkin biopsy specimenHypersensitivity reactionsVaccine doseBiopsy specimenHistopathologic examinationSeries studyRetrospective case series studyYale-New Haven HospitalFirst vaccine doseTertiary medical centerFirst-dose reactionsRelevant medical historyVaccine adverse effectsCoronavirus disease 2019 (COVID-19) pandemicDemographic informationEmergency use authorizationPfizer-BioNTech vaccinePatient demographic informationLocalized hypersensitivity reactionEffectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021
Britton A, Slifka K, Edens C, Nanduri SA, Bart S, Shang N, Harizaj A, Armstrong J, Xu K, Ehrlich HY, Soda E, Derado G, Verani JR, Schrag SJ, Jernigan JA, Leung VH, Parikh S. Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021. MMWR Morbidity And Mortality Weekly Report 2021, 70: 396-401. PMID: 33735160, PMCID: PMC7976620, DOI: 10.15585/mmwr.mm7011e3.Peer-Reviewed Original ResearchConceptsPfizer-BioNTech COVID-19 vaccineSkilled nursing facilitiesCOVID-19 vaccineLong-term care facilitiesSNF residentsNursing facilitiesCOVID-19 vaccine clinical trialsCOVID-19-associated morbidityEarly COVID-19 vaccinationSARS-CoV-2 infectionElectronic chart reviewVaccine effectiveness dataUnderlying medical conditionsVaccine clinical trialsCOVID-19 vaccinationPfizer-BioNTech vaccineSARS-CoV-2Long-term care programsStaff membersChart reviewFirst doseVaccination statusPartial vaccinationVaccine impactSecond dose
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply